How The Inflation Reduction Act Affects Medicare
The Inflation Reduction Act brings major changes to Medicare benefits, with the most significant impact on prescription drug costs. Starting in 2025, Medicare Part D beneficiaries will have their out-of-pocket drug expenses capped at $2,000 annually, and monthly insulin copays will be limited to $35.
Medicare will also begin negotiating prices for high-cost medications, starting with 10 drugs in 2026 and expanding to 60 by 2029, while implementing penalties for drug companies that raise prices above inflation rates.
Additional benefits include free recommended vaccines under Medicare Part D, enhanced premium subsidies for qualifying low-income beneficiaries, and improved access to affordable biosimilar medications under Part B. These changes will be implemented gradually over the next few years.
If you're eligible for the low-income subsidy program (LSI or Extra Help) or have a limited income up to 150% of the Federal Poverty Level, the Inflation Reduction Act may reduce or eliminate various Medicare Part D costs, including premiums, deductibles, and copays.
For more information about Medicare, please speak with a Senior Healthcare Solutions Medicare expert today at 866-633-4427.
Blog post: https://seniorhealthcaresolutions.com...